AT-130

AT-130

• CAS Number: 211364-06-6
• UNSPSC Description: AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells[1][2][3].
• Target Antigen: DNA/RNA Synthesis; HBV
• Type: Reference compound
• Related Pathways: Anti-infection;Cell Cycle/DNA Damage
• Applications: COVID-19-anti-virus
• Field of Research: Cancer; Infection
• Assay Protocol: https://www.medchemexpress.com/at-130.html
• Purity: 98.39
• Solubility: DMSO : 25 mg/mL (ultrasonic)
• Smiles: O=C(N/C(C(N1CCCCC1)=O)=C(Br)\C2=CC=CC=C2OC)C3=CC=C([N+]([O-])=O)C=C3
• Molecular Weight: 488.33
• References & Citations: [1]William E Delaney 4th, et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother. 2002 Sep;46(9):3057-60.|[2]R B Perni , et al. Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2687-90.|[3]J J Feld, et al. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 2007 Nov;76(2):168-77.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported